Pfizer Inc. (NYSE:PFE - Get Free Report) shot up 2.6% on Monday . The stock traded as high as $23.02 and last traded at $22.87. 29,416,652 shares traded hands during trading, a decline of 27% from the average session volume of 40,488,144 shares. The stock had previously closed at $22.28.
Wall Street Analyst Weigh In
PFE has been the subject of several recent research reports. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.
View Our Latest Research Report on Pfizer
Pfizer Trading Up 1.0%
The stock has a market capitalization of $129.77 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58. The company's 50-day moving average is $23.65 and its 200-day moving average is $25.36. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm posted $0.82 earnings per share. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer's payout ratio is currently 124.64%.
Hedge Funds Weigh In On Pfizer
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter worth $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter worth $27,000. Gould Capital LLC lifted its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter valued at $27,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
